Sulfasalazine Monitoring and Hepatotoxic Effects

Laboratory Monitoring and Hepatotoxicity

• The American College of Rheumatology recommends monitoring complete blood count, liver function tests, and renal function within the first 1-2 months of sulfasalazine usage and every 3-4 months thereafter, with a strength of evidence based on clinical guidelines 1
• If clinically relevant elevations in liver function tests or decreased neutrophil or platelet counts are found, decreasing or temporarily holding the sulfasalazine dose is conditionally recommended, based on expert opinion and clinical experience 1

Differential Diagnosis for Unconjugated Hyperbilirubinemia

• Consider Gilbert syndrome, a benign hereditary disorder affecting 5% of the population, characterized by reduced activity of glucuronosyltransferase enzyme, as a potential cause of unconjugated hyperbilirubinemia in patients on sulfasalazine, with a moderate level of evidence from observational studies 2